NASDAQ$TRAW
Traws Pharma Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported financial results for full year 2020 and provided a business update.
Onconova Therapeutics reported its full year 2020 financial results, with a net loss of $25.2 million and cash and cash equivalents of $19.0 million as of December 31, 2020. The company is advancing its lead product ON 123300 into clinical trials and supporting investigator-initiated studies with oral rigosertib.
- Submitted an Investigational New Drug application to the FDA for a Phase 1 study in advanced cancers.
- Received clearance from the FDA to begin the Phase 1 study and received IRB approval at the first site.
- Partner HanX Pharmaceuticals continues enrolling patients in a Phase 1 dose-escalation study with ON 123300 in China.
- Supporting investigator-initiated studies exploring the use of oral rigosertib for cancers driven by mutation of the RAS gene.
Headline financials
Revenue & EPS history
Onconova · Revenue · Quarterly
$57K
Forward guidance
The Company expects that its cash and cash equivalents as of February 28, 2021 will be sufficient to fund ongoing clinical trials and business operations for more than eighteen months.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2020
-0.7%
Avg return
Earnings day
-2.6%
Avg return
5 days after
-5.0%
Avg return
30 days after
25%
9 / 36 earnings
Positive
+22.6%
Q3 2025
Best reaction
-22.6%
Q4 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +15.3% | — | — | |
| Q4 2026 | -22.6% | -12.6% | +18.2% | |
| Q3 2025 | +22.6% | +19.2% | +31.6% | |
| Q2 2025 | -1.2% | -18.3% | +16.5% | |
| Q1 2025 | -3.6% | +1.4% | +2.1% | |
| Q4 2024 | +6.0% | -1.0% | -30.5% | |
| Q3 2024 | -11.7% | -16.8% | -17.7% | |
| Q2 2024 | -2.7% | +5.4% | -5.4% | |
| Q1 2024 | -2.5% | -1.5% | -9.1% | |
| Q4 2023 | -1.5% | -19.8% | -34.7% | |
| Q3 2023 | -3.1% | +0.0% | +15.4% | |
| Q2 2023 | -2.0% | -11.2% | -20.4% | |
| Q1 2023 | -4.0% | -5.3% | +53.3% | |
| Q4 2022 | -3.9% | -5.3% | +51.3% | |
| Q3 2022 | +18.3% | +36.6% | +7.0% | |
| Q2 2022 | +3.9% | -1.6% | -10.1% | |
| Q1 2022 | -1.6% | -2.1% | -26.1% | |
| Q4 2021 | +10.0% | +13.7% | +0.6% | |
| Q3 2021 | +1.2% | -1.5% | -18.3% | |
| Q2 2021 | -4.4% | -11.8% | -1.2% | |
| Q1 2021 | -3.1% | -9.0% | -26.4% | |
| Q4 2020 | +0.0% | -3.6% | -97.0% | |
| Q3 2020 | +0.0% | +3.8% | +42.3% | |
| Q2 2020 | -3.6% | -6.4% | -79.1% | |
| Q1 2020 | +0.0% | +5.6% | +69.4% | |
| Q3 2019 | -7.1% | -16.7% | -35.7% | |
| Q2 2019 | -2.1% | -5.6% | +7.3% | |
| Q1 2019 | -6.3% | -11.5% | -15.9% | |
| Q3 2018 | -11.5% | -3.1% | -25.1% | |
| Q2 2018 | -9.1% | -6.8% | +11.4% | |
| Q1 2018 | -5.4% | -2.7% | +40.5% | |
| Q3 2017 | -2.1% | -16.8% | -22.1% | |
| Q2 2017 | -0.5% | -16.7% | -19.3% | |
| Q1 2017 | -0.5% | -0.5% | -9.0% | |
| Q3 2016 | +11.0% | +28.7% | -15.8% | |
| Q2 2016 | +2.5% | +4.2% | -21.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro